| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4198530 | Health Policy | 2009 | 10 Pages |
Abstract
The cost of FDG-PET is mainly influenced by the cost of the radiopharmaceutical. Therefore, the latter rather than the operational time should be reduced in order to improve its cost-effectiveness.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
![Activity-based costing evaluation of a [18F]-fludeoxyglucose positron emission tomography study](/preview/png/4198530.png "First Page Preview: Activity-based costing evaluation of a [18F]-fludeoxyglucose positron emission tomography study")
Authors
Bruno Krug, Annie Van Zanten, Anne-Sophie Pirson, Ralph Crott, Thierry Vander Borght,